Biofrontera AG

  • WKN: 604611
  • ISIN: DE0006046113
  • Land: Deutschland

Nachricht vom 10.01.2020 | 11:00

Biofrontera AG: Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter

Biofrontera AG / Key word(s): Development of Sales/Annual Results
Biofrontera AG: Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter

10-Jan-2020 / 11:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter

Leverkusen, Germany, 10 January 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its results for the first nine months ended September 30, 2019. At the same time, the guidance for fiscal 2019 has been adjusted.

The preliminary, unaudited turnover of the Biofrontera Group for the period 1 January to 31 December 2019 was between 31.1 and 31.4 million euros, slightly above the last guidance. This corresponds to a sales growth of almost 50% compared to the previous year, with pure product sales increasing by approximately 46%.

Preliminary revenues from product sales in the USA are expected to be around EUR 23.3 million, compared to EUR 14.9 million in the same period of 2018 (ca. +57%). In Germany, revenues from product sales will amount to approx. EUR 4.6 million, compared with EUR 3.3 million for the full year 2018 (ca. +40%). Revenues for Europe excluding Germany were roughly on par with the previous year, with rising revenues in Spain and the United Kingdom offsetting lower revenues with license partners.

Sales in the fourth quarter amounted to approximately EUR 12.2 million, compared to EUR 6.6 million in the previous year. Biofrontera thus achieved the highest quarterly sales in its corporate history. Decisive for the strong growth was again the steadily growing US business, as well as the sales increases in Germany and Spain. The latter were mainly due to the European approval for Ameluz(R) in combination with daylight PDT. Due to a price increase of about 6% for Ameluz(R) in the USA effective January 1, 2020, the product was in some practices stocked up in December 2019, also contributing to the strong sales growth in the last quarter.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: ir@biofrontera.com


10-Jan-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

HELMA Eigenheimbau: Klarer Kauf

Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.

News im Fokus

Munich Re beschließt Aktienrückkauf

26. Februar 2020, 13:17

Aktuelle Research-Studie

Schloss Wachenheim AG

Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Kaufen

27. Februar 2020